LifeMine Therapeutics
Develops fungal genome-derived therapeutics for organ transplant rejection
$263MSeries D+Series E
Role not disclosedLoading investors…
Activity from announced rounds
Develops fungal genome-derived therapeutics for organ transplant rejection
Developing AI systems to discover and design new materials for clean energy and chipmaking
Pitching Bezos Expeditions? Send the deck from a free RoundOS data room and see which pages they read.
Create a free room